根据美国证券交易委员会最新披露的文件显示，坎伯兰药业（Cumberland Pharmaceuticals）与Apotex公司签订的协议中包含特殊条款：若满足特定条件，其中一方需向对方支付高达400万美元的终止费用。
该条款明确了交易终止的触发情形，体现出双方对合作关系的风险管控。这笔七位数的违约金设置，既为协议执行提供了保障机制，也反映出商业合作中常见的风险平衡设计。
根据美国证券交易委员会最新披露的文件显示，坎伯兰药业（Cumberland Pharmaceuticals）与Apotex公司签订的协议中包含特殊条款：若满足特定条件，其中一方需向对方支付高达400万美元的终止费用。
该条款明确了交易终止的触发情形，体现出双方对合作关系的风险管控。这笔七位数的违约金设置，既为协议执行提供了保障机制，也反映出商业合作中常见的风险平衡设计。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.